AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30783814 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib dose reduction (< 40 mg/day)
Number of subjects: 319
Study 30783814 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg/day
Number of subjects: 319
Study 30783814 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib and gefitinib beyond progression
Number of subjects: 319
Study 28488943 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-blocking (BB) glasses
Number of subjects: 20
Study 28488943 — intervention group
Group type: COMPARATOR
Intervention: Clear glasses (placebo)
Number of subjects: 20
Study 28488943 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 25182625 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry - FEV1%predicted
Number of subjects: 3080
Study 25182625 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry - FEV1/FVC
Number of subjects: 3080
Study 25182625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary CT biomarker - perc15
Number of subjects: 3080
Study 25182625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary CT biomarker - pi10
Number of subjects: 3080
Study 25182625 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium volume
Number of subjects: 3080
Study 24325051 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenxin Granule (WG), 9 g each time, three times daily for 90 days
Number of subjects: 65
Study 24325051 — intervention group
Group type: COMPARATOR
Intervention: Routine therapies (ACEI and metoprolol)
Number of subjects: 65
Study 21458810 — intervention group
Group type: COMPARATOR
Intervention: Systemic methotrexate (MTX), n=13
Number of subjects: 44
Study 21458810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization with MTX and gelatin sponge (GS), n=15
Number of subjects: 44
Study 21458810 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoembolization with MTX and polyvinyl alcohol (PVA), n=16
Number of subjects: 44
Study 18005494 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Cognitive Therapy for Early Psychosis (ACE)
Number of subjects: 62
Study 18005494 — intervention group
Group type: COMPARATOR
Intervention: Befriending
Number of subjects: 62
Study 16096516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 0
Study 16096516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12393109 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain scores via visual analog scale (0‐100) in depressed patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: COMPARATOR
Intervention: Postoperative pain scores via visual analog scale (0‐100) in control patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: EXPERIMENTAL
Intervention: Current perception thresholds at 5 Hz in depressed patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: EXPERIMENTAL
Intervention: Current perception thresholds at 250 Hz in depressed patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: EXPERIMENTAL
Intervention: Current perception thresholds at 2000 Hz in depressed patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: COMPARATOR
Intervention: Current perception thresholds at 5 Hz in control patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: COMPARATOR
Intervention: Current perception thresholds at 250 Hz in control patients
Number of subjects: 60
Study 12393109 — intervention group
Group type: COMPARATOR
Intervention: Current perception thresholds at 2000 Hz in control patients
Number of subjects: 60
Study 10025601 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg rhDNase
Number of subjects: 17
Study 10025601 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 microg/kg rhDNase
Number of subjects: 17
Study 10025601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 10025601 — intervention group
Group type: COMPARATOR
Intervention: All groups (25 microg/kg, 125 microg/kg, and placebo)
Number of subjects: 17
Study 10025601 — intervention group
Group type: EXPERIMENTAL
Intervention: rhDNase
Number of subjects: 17
Study 10025601 — intervention group
Group type: EXPERIMENTAL
Intervention: IV administration of rhDNase
Number of subjects: 17
Study 10025601 — intervention group
Group type: EXPERIMENTAL
Intervention: SC administration of rhDNase
Number of subjects: 17
Study 7582381 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (azathioprine + prednisolone + CsA)
Number of subjects: 26
Study 7582381 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (azathioprine + prednisolone)
Number of subjects: 26
Study 1702010 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and bleomycin with hyperthermia
Number of subjects: 101
Study 1702010 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and bleomycin
Number of subjects: 101
Study 380611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethamsylate (Dicynene)
Number of subjects: 100
Study 380611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31646650 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ)
Number of subjects: 41
Study 31646650 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 31099698 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus specialty palliative care (PC)
Number of subjects: 30
Study 31099698 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 30
Study 28073907 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg once daily for one week followed by 850 mg twice daily for three weeks)
Number of subjects: 34
Study 28073907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28073907 — intervention group
Group type: COMPARATOR
Intervention: Metformin vs Placebo
Number of subjects: 34
Study 25847207 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS‐AE (automatic EPAP)
Number of subjects: 60
Study 25847207 — intervention group
Group type: COMPARATOR
Intervention: S/T technology (control)
Number of subjects: 60
Study 25847207 — intervention group
Group type: EXPERIMENTAL
Intervention: AVAPS‐AE
Number of subjects: 60
Study 23143044 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% glucose acetated Ringer's solution (Group I)
Number of subjects: 45
Study 23143044 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% glucose acetated Ringer's solution (Group II)
Number of subjects: 45
Study 23143044 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose acetated Ringer's solution (Group III)
Number of subjects: 45
Study 21211641 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of specific immunotherapy (IT3)
Number of subjects: 239
Study 21211641 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of specific immunotherapy (IT5)
Number of subjects: 239
Study 21211641 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 239
Study 19176282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (MedDiet)
Number of subjects: 808
Study 19176282 — intervention group
Group type: EXPERIMENTAL
Intervention: Components of the Mediterranean diet (olive oil, legumes, red wine)
Number of subjects: 808
Study 16530721 — intervention group
Group type: COMPARATOR
Intervention: Backboard footstrap
Number of subjects: 22
Study 16530721 — intervention group
Group type: COMPARATOR
Intervention: Change in handle configuration on the stairchair
Number of subjects: 22
Study 16530721 — intervention group
Group type: COMPARATOR
Intervention: Backboard wheeler
Number of subjects: 22
Study 16530721 — intervention group
Group type: COMPARATOR
Intervention: Descent control system (DCS)
Number of subjects: 22
Study 14976386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dithranol in bio-wash-oil
Number of subjects: 64
Study 14976386 — intervention group
Group type: COMPARATOR
Intervention: Micanol cream
Number of subjects: 64
Study 14976386 — intervention group
Group type: COMPARATOR
Intervention: Micanol cream in bio-wash-oil
Number of subjects: 64
Study 11803348 — intervention group
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (ATG) 1.25 mg/kg on alternate days, starting at a median interval of 11 days after BMT
Number of subjects: 18
Study 11803348 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical unrelated donor transplants)
Number of subjects: 18
Study 11803348 — intervention group
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin (ATG)
Number of subjects: 18
Study 9544598 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care
Number of subjects: 63
Study 9544598 — intervention group
Group type: COMPARATOR
Intervention: Traditional inpatient care
Number of subjects: 63
Study 9422123 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (solvent/detergent virus-inactivated plasma)
Number of subjects: 14
Study 9422123 — intervention group
Group type: COMPARATOR
Intervention: FFP (fresh frozen plasma)
Number of subjects: 14
Study 3183937 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-0 nylon
Number of subjects: 85
Study 3183937 — intervention group
Group type: COMPARATOR
Intervention: 9-0 nylon
Number of subjects: 85
Study 3183937 — intervention group
Group type: COMPARATOR
Intervention: 10-0 polyester
Number of subjects: 85
Study 29573659 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) derived from a conduct disorder genome wide association study
Number of subjects: 561
Study 28318748 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet distraction provided by a child life specialist
Number of subjects: 30
Study 28318748 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 30
Study 26214775 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic application of SEC
Number of subjects: 92
Study 26214775 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of lymphocytes activated by SEC
Number of subjects: 92
Study 26214775 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 23951950 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical anchors
Number of subjects: 0
Study 23951950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vague quantifiers
Number of subjects: 0
Study 23951950 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific associations between quantifiers
Number of subjects: 0
Study 21164121 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz repetitive transcranial magnetic stimulation over the right-hemispheric inferior frontal gyrus
Number of subjects: 0
Study 21164121 — intervention group
Group type: COMPARATOR
Intervention: Control group (vertex stimulation)
Number of subjects: 0
Study 18791411 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA (0.1 mmol/kg bodyweight)
Number of subjects: 12
Study 18791411 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA (0.1 mmol/kg bodyweight)
Number of subjects: 12
Study 15115901 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral oestradiol for 3 months
Number of subjects: 18
Study 15115901 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 18
Study 11430611 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle teaching
Number of subjects: 77
Study 11430611 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour modification
Number of subjects: 77
Study 11430611 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study 9704766 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasonography (with sonohysterography if endometrial thickness was >4 mm)
Number of subjects: 53
Study 9704766 — intervention group
Group type: COMPARATOR
Intervention: Office hysteroscopy
Number of subjects: 53
Study 7989942 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF at 5, 10, or 20 micrograms/kg, administered subcutaneously (SC) on days 4 to 13 of each cycle
Number of subjects: 290
Study 7989942 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF at 5, 10, or 20 micrograms/kg
Number of subjects: 290
Study 7989942 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms/kg of rhGM-CSF
Number of subjects: 290
Study 7989942 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 290
Study 7989942 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 and 20 micrograms/kg rhGM-CSF
Number of subjects: 290
Study 7989942 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg rhGM-CSF
Number of subjects: 290
Study 3185315 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood pressure monitor
Number of subjects: 132
Study 3185315 — intervention group
Group type: COMPARATOR
Intervention: Standard mercury manometer
Number of subjects: 132
Study 29119246 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed Endurance Training (SET)
Number of subjects: 39
Study 29119246 — intervention group
Group type: COMPARATOR
Intervention: Small-Sided Game Training (SSG)
Number of subjects: 39
Study 27130911 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated celiac disease (CD)
Number of subjects: 45
Study 27130911 — intervention group
Group type: COMPARATOR
Intervention: Self-reported NCGS
Number of subjects: 45
Study 27130911 — intervention group
Group type: COMPARATOR
Intervention: Treated celiac disease (CD)
Number of subjects: 45
Study 27130911 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 45
Study 23983096 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group (N=94)
Number of subjects: 386
Study 23983096 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (N=96)
Number of subjects: 386
Study 23983096 — intervention group
Group type: COMPARATOR
Intervention: Observational group (N=196)
Number of subjects: 386
Study 23983096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N=190)
Number of subjects: 386
Study 22879441 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized rehabilitation program that commenced in the ICU and continued for 8 weeks post-discharge as an outpatient program.
Number of subjects: 74
Study 22879441 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient classes following the rehabilitation program.
Number of subjects: 74
Study 22879441 — intervention group
Group type: COMPARATOR
Intervention: Standard care (local standard care).
Number of subjects: 74
Study 20881947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release d-amphetamine (SR-AMP) 0, 30, and 60 mg/day
Number of subjects: 8
Study 20881947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release d-amphetamine (SR-AMP)
Number of subjects: 8
Study 18591600 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbert screw fixation
Number of subjects: 71
Study 18591600 — intervention group
Group type: COMPARATOR
Intervention: Below-elbow plaster cast immobilisation
Number of subjects: 71
Study 18591600 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 15899030 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab therapy (discontinued after 3 years)
Number of subjects: 42
Study 15899030 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with infliximab
Number of subjects: 42
Study 11756596 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1b (Betaferon)
Number of subjects: 718
Study 11756596 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual MRI outcomes
Number of subjects: 718
Study 11756596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative number of active T2 lesions
Number of subjects: 718
Study 11756596 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly imaging in a subgroup of 125 patients
Number of subjects: 718
Study 9653638 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping-oriented group therapy
Number of subjects: 0
Study 9653638 — intervention group
Group type: COMPARATOR
Intervention: Unstructured supportive group therapy
Number of subjects: 0
Study 7925148 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 23
Study 3246215 — intervention group
Group type: EXPERIMENTAL
Intervention: Clocapramine
Number of subjects: 52
Study 3246215 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride
Number of subjects: 52
Study 31721398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 49
Study 31721398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone + Naloxegol
Number of subjects: 49
Study 31721398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31721398 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone + Placebo
Number of subjects: 49
Study 31323005 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3 days/week, 20-75 min per day at 45-75% maximum heart rate for 12 weeks)
Number of subjects: 45
Study 31323005 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicine + training (GnRHa once a month, 1 mL every 4 weeks by intramuscular injection + aerobic training)
Number of subjects: 45
Study 31323005 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (4 weeks after the last training session)
Number of subjects: 45
Study 31323005 — intervention group
Group type: COMPARATOR
Intervention: Medication group (GnRHa only)
Number of subjects: 45
Study 27743396 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal implants placed 2 mm below the alveolar crest
Number of subjects: 23
Study 27743396 — intervention group
Group type: COMPARATOR
Intervention: Crestal implants placed at bone level
Number of subjects: 23
Study 26630435 — intervention group
Group type: EXPERIMENTAL
Intervention: activL TDR
Number of subjects: 324
Study 23700728 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Devine's operation (treatment group)
Number of subjects: 20
Study 23700728 — intervention group
Group type: COMPARATOR
Intervention: Circumcision (control group)
Number of subjects: 20
Study 21292200 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided sevoflurane anesthesia
Number of subjects: 160
Study 21292200 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided sevoflurane anesthesia
Number of subjects: 160
Study 21292200 — intervention group
Group type: COMPARATOR
Intervention: Standard practice group (clinical parameters only)
Number of subjects: 160
Study 21292200 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 160
Study 21292200 — intervention group
Group type: EXPERIMENTAL
Intervention: AAI-guided anesthesia
Number of subjects: 160
Study 21292200 — intervention group
Group type: COMPARATOR
Intervention: Standard practice group
Number of subjects: 160
Study 19757982 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal combination therapy (Hypericum perforatum and Vitex agnus-castus)
Number of subjects: 14
Study 19757982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17078279 — intervention group
Group type: COMPARATOR
Intervention: 2-layer technique (Group B)
Number of subjects: 40
Study 17078279 — intervention group
Group type: EXPERIMENTAL
Intervention: microlayer technique (Group C)
Number of subjects: 40
Study 14765699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding mode closed-loop FES controller
Number of subjects: 0
Study 14765699 — intervention group
Group type: COMPARATOR
Intervention: Open-loop controlled FES devices
Number of subjects: 0
Study 11769822 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 13
Study 11769822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9174317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (0.1 mL intradermal injection of 0.5%)
Number of subjects: 10
Study 9174317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine plus Morphine (0.1 mL of 0.5 mg of morphine plus lidocaine 1%)
Number of subjects: 10
Study 9174317 — intervention group
Group type: COMPARATOR
Intervention: Reference site (no injection)
Number of subjects: 10
Study 8196158 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate haemodialysis/filtration
Number of subjects: 8
Study 8196158 — intervention group
Group type: COMPARATOR
Intervention: Acetate haemodialysis/filtration
Number of subjects: 8
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension (HTN) prevalence
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 45 and older
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweightness
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference > 102 cm in men and > 88 cm in women
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Light occupational physical activity
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking or riding a bicycle for < 5 days/week
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of sport activity
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Khat use
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Household size of two
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Household size of three or more
Number of subjects: 312
Study 31664909 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of HTN
Number of subjects: 312
Study 29394511 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (EX/RP)
Number of subjects: 100
Study 29394511 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 100
Study 29394511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27059387 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol I (100 ml of 350 mg iodine/ml iodinated CM; n=16)
Number of subjects: 33
Study 27059387 — intervention group
Group type: COMPARATOR
Intervention: Protocol II (50 ml of 350 mg iodine/ml iodinated CM; n=17)
Number of subjects: 33